Bajaj Health has also extended the offer for Pimavanserin to several leading pharma companies to ensure availability in ...

VANCOUVER - InMed Pharmaceuticals Inc. (NASDAQ: INM), a small-cap biotech company with a market capitalization of $2.21 million, has announced the selection of an intravitreal (IVT) formulation, ...

Mumbai: Bajaj Healthcare Limited has announced that it has received approval from the Drug Controller General of India (DCGI) ...

Alembic Pharmaceuticals reported a 23.29% decline in Q3 FY25 net profit at ₹138.42 crore, despite a 3.81% revenue increase to ...

Sun Pharma reported a 15% YoY rise in Q3FY25 profit to Rs 2,903 crore, surpassing estimates. Revenue grew 10% to Rs 13,675.5 ...

Sun Pharma announced a 15 per cent year-on-year (YoY) increase, reaching ₹2,903 crore for the quarter ending December 2024.

Alembic Pharmaceuticals tumbled 3.43% to Rs 905 after the company's consolidated net profit tumbled 23.29% to Rs 138.42 crore in Q3 FY25, compared with Rs 180.45 crore posted in Q3 FY24.

Bajaj Healthcare has received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule.

Bajaj Healthcare has received approval from India's Drug Controller General to manufacture Pimavanserin, a drug for Parkinson's-related hallucinations and delusions. Pimavanserin, already popular in ...

Citi Pharma Limited (PSX: CPHL) was incorporated in Pakistan as a private limited company in 2012 and was converted into a ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...